Pathology Outlines - Programmed death-1 (PD-1)
2021年8月23日 · Programmed cell death-1 (PD-1) Co-inhibitory checkpoint receptor 1 of 5 receptors within the CD28 coreceptor family [CD28, inducible T cell costimulatory (ICOS), …
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic ...
PD-L1 expression by tumor cells and TILs assessed by immunohistochemistry (IHC) is considered the most reliable predictive marker for response to immunotherapy in different …
PD-L1免疫组化检测 - 知乎 - 知乎专栏
PD-L1免疫组化检测 是预测PD-1或PD-L1疗效的一种简单有效的方法，它是通过检测肿瘤细胞（TC）或免疫细胞（IC）表面的PD-L1表达量，进而推测PD-L1抑制剂疗效的方法。 目 …
PD−L1 immunostaining: what pathologists need to know
2021年10月25日 · Each checkpoint pathway decreases immune activation through intracellular signaling mechanisms and thus negatively regulates the effector immune cells by inducing T …
靶点解惑Plus | 结合6位科研人的WB/IHC真实案例，精讲PD1/PD …
PD1是一种在活化的 T 细胞中表达的免疫抑制受体，参与调节 T 细胞功能，在诱导和维持对自身的免疫耐受中起关键作用。 PD-L1 可结合活化T细胞表面的B7.1和PD1 降低细胞毒性。 PD1/PD …
PD-1/PD-L1免疫组化检测是什么？一文详探究竟！ | 蓝沙生物
2024年1月22日 · PD-1（Programmed cell death protein 1，程序性死亡受体1），又称CD279（分化簇 279）， 是人类体内由 PDCD1 基因编码的蛋白质。 PD-1是T细胞和B细胞上的细胞表面 …
PD-1 and PD-L1 in cancer immunotherapy: clinical implications …
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. Binding of PD-1 to its ligand, programmed …
PD-1 transcriptomic landscape across cancers and implications for ...
5 天之前 · Some reports have suggested that positive PD-1 expression by IHC on tumor infiltrating lymphocytes (TILs) may predict better outcome after ICIs 20. However, the exact …
PD-L1 as a biomarker of response to immune-checkpoint inhibitors - Nature
2021年2月12日 · PD-L1 expression, which can be detected using immunohistochemistry (IHC), is found on both tumour cells and immune cells and is a useful, yet imperfect, predictive …
Optimization and validation of PD-L1 immunohistochemistry …
2018年6月26日 · Several immunohistochemistry (IHC) assays have been developed to assess tumor programmed death-ligand 1 (PD-L1) expression levels in patients who are candidates …